



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

Date: November 6, 2023

To,

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 543434	National Stock Exchange of India Limited Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 NSE Symbol: SUPRIYA
-----------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dear Sir/Madam,

Subject: Press Release- Supriya Lifescience Ltd signs agreement with Kalinga Institute of Technology for further development of wound healing gel

Pursuant to the relevant provisions of the SEBI Listing Regulations, we are enclosing herewith Press Release “Supriya Lifescience Ltd signs agreement with Kalinga Institute of Technology for further development of wound healing gel”.

Request you to kindly take the same on record.

Thanking you,

For Supriya Lifescience Limited

**Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973**

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE



SUPRIYA LIFESCIENCE LTD.

Supriya Lifescience Ltd signs agreement with Kalinga Institute of Technology for further development of wound healing gel

- This gel is one of a kind onsite Protein Matrix Technology in advance wound care segment.

Mumbai, November 06, 2023: Supriya Lifescience, one of India's leading speciality active pharmaceutical ingredients (API) manufacturing company and CDMO signs an agreement with Kalinga Institute of Technology for further development of **GelHeal**, a protein-based crosslinked Hydrogel. The gel-based cream is mapped out and designed taking into account the In-Situ scaffolding for mechanical support into the deep wounds and scar-free skin regeneration.

The gel-based cream may prove to be prolific in easing and healing not only third-degree wounds, cuts, bite/ballistic wounds but also diabetic foot ulcers, pressure ulcers, venous leg ulcers and surgery wounds.

This radical shift in dermatology and skin grafting would also now cater to scar-free skin, not mandating repetitive hospitalization through the topical formulation for skin regeneration gel, thus proving cost-effective and less time-consuming medical solution for many.

With such functionalities, GelHeal also fabricates mechanisms for preventing infection, avoiding over-drying while accommodating a moist environment, mechanical support for strain-less wound closure and Scaffold Support Skin Regeneration Support thus resulting in scar-free skin.

Dr. Satish Wagh, Founder and Chairman, Supriya Lifescience Ltd says, *"As we have already demarcated positive change by recently signing an agreement to develop Quickblue which is the oral cancer detection kit in collaboration with Kalinga Institute of Industrial Technology, we are looking forward in aiding more innovative products like GelHeal, the simplest and cheapest wound healing gel".*

Dr. Satish Wagh further said, *"Supriya Lifescience has established itself as a CDMO player over decades, Supriya Lifescience is putting a step forward into diversification of our business by banking on our world-class CDMO capabilities and offering niche products for healthcare needs. We believe more and more of such products will establish Supriya Lifescience Ltd as an integrated healthcare provider."*

About Supriya Lifescience Ltd:

Established in the year 1987, Supriya Lifescience Ltd. is a global leading manufacturer of Active pharmaceutical Ingredients. Our state-of-the-art facility is certified by the USFDA, EDQM, EUGMP, NMPA & Health Canada. The facility is located in Khed, District Ratnagiri and is headquartered in Mumbai, India.

Backed by strong R&D, 14 active USDMFs, 8 active CEPs and worldwide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Core business is driven by Ethical values and EHS standards. The company's focus is to develop APIs and Intermediates for both Innovators and generic companies and we also partner exclusively as CDMO.

For more details:

Supriya Lifescience Ltd	Dentsu Creative PR
Krishna Raghunathan	Abhishek Chawande
T: 022-4033 2749	M: 9664516774
e-mail: cfo@supriyalifescience.com	e-mail: abhishek.chawande@dentsu.com